In vitro activity of ertapenem against selected respiratory pathogens

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 5, 2004, Pages 944-951

  Marchese, Anna ^a   Gualco, L ^a   Schito, A M ^a   Debbia, E A ^a   Schito, G C ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Bactericidal activity; Carbapenems; Interactions; Streptococcus pneumoniae; Time kill

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAMASE; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERTAPENEM; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; METICILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COMMUNICABLE DISEASE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENCY; DRUG POTENTIATION; ENZYME SYNTHESIS; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PHENOTYPE; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

BACTERIA; BETA-LACTAMS; HUMANS; LACTAMS; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 8844269107     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh445     Document Type: Article

References (10)

1. Fauci, A. S. (2001). Infectious diseases: considerations for the 21st century. Clinical Infectious Diseases 32, 675-85.
2. Mandell, L. A., Bartlett, J. G., Dowell, S. F. et al. (2003). Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clinical Infectious Diseases 37, 1405-33.
3. Felmingham, D. (2002). Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin. Journal of Infection 44, Suppl. A, 3-10.
4. National Committee for Clinical Laboratory Standards. (2004). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Sixth Edition: Approved Standard M7-A6 and M100-S14. NCCLS, Wayne, PA, USA.
5. National Committee for Clinical Laboratory Standards. (1999). Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. NCCLS, Wayne, PA, USA.
6. Livermore, D. M., Sefton, A. M. & Scott, G. M. (2003). Properties and potential of ertapenem. Journal of Antimicrobial Chemotherapy 52, 331-44.
7. Jones, R. N. (2001). In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains. Journal of Chemotherapy 13, 363-76.
8. Pankuch, G. A., Davies, T. A., Jacobs, M. R. et al. (2002). Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents. Antimicrobial Agents and Chemotherapy 46 42-6.
9. Ortiz-Ruiz, G., Vetter, N., Isaacs, R. et al. (2004). Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. Journal of Antimicrobial Chemotherapy 53 Suppl. S2, ii59-66.
10. Marchese, A., Mannelli, S., Tonoli, E. et al. (2001). Prevalence of antimicrobial resistance in Streptococcus pneumoniae circulating in Italy: results of the Italian Epidemiological Observatory Survey (1997-1999). Microbial Drug Resistance 7, 277-87.